接受药物血栓预防的危重患者静脉血栓栓塞症风险评估模型的效能:PREVENT试验的事后分析
该研究为PREVENT试验的事后分析,纳入2003例接受药物血栓预防的危重患者,评估ICU-VTE、Kucher、Intermountain、Caprini、Padua和IMPROVE六种VTE风险评估模型的诊断效能。198例(9.9%)发生VTE。多因素logistic回归显示,VTE的独立预测因素为急性生理与慢性健康评估II评分、既往制动、股静脉中心静脉导管和侵入性机械通气。除Caprini模型AUC为0.64(95%CI 0.60-0.68)外,其余模型AUC均<0.60。Caprini、Padua和Intermountain模型敏感性高(>85%)但特异性低(<20%);ICU-VTE、Kucher和IMPROVE模型敏感性低(<15%)但特异性高(>85%)。所有研究界值的阳性预测值均低(<20%),阴性预测值多>90%。按风险模型分层后,辅助气压压缩与单纯药物预防的效应在各亚组间无差异(交互作用P>.05)。
要点
- 在2003例接受药物血栓预防的危重患者中,198例(9.9%)发生VTE。
- 除Caprini模型AUC为0.64(95%CI 0.60-0.68)外,所有风险评估模型AUC均<0.60。
- Caprini、Padua和Intermountain模型敏感性>85%但特异性<20%;ICU-VTE、Kucher和IMPROVE模型敏感性<15%但特异性>85%。
- 所有研究界值的阳性预测值均<20%,阴性预测值多>90%。
- 按风险模型分层后,辅助气压压缩与单纯药物预防的效应在各亚组间无差异(交互作用P>.05)。
适用人群与场景
- 接受药物血栓预防的危重患者,来自PREVENT试验人群。
研究设计与关键结果
- 研究类型:PREVENT试验的事后分析,纳入2003例接受药物血栓预防的危重患者,198例(9.9%)发生VTE。
- 多因素logistic回归分析显示,VTE的独立预测因素为急性生理与慢性健康评估II评分、既往制动、股静脉中心静脉导管和侵入性机械通气。
- 所有风险评估模型AUC均<0.60,仅Caprini模型AUC为0.64(95%CI 0.60-0.68)。
- Caprini、Padua和Intermountain模型敏感性>85%、特异性<20%;ICU-VTE、Kucher和IMPROVE模型敏感性<15%、特异性>85%。
- 所有研究界值的阳性预测值均<20%,阴性预测值多>90%。
- 按风险模型将患者分为高风险与低风险亚组后,辅助气压压缩与单纯药物预防的效应在各亚组间无差异(交互作用P>.05)。
证据类型、等级与局限
- 证据类型:PREVENT试验的事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,VTE风险评估模型在接受药物血栓预防的危重患者中效能差,均未能识别可能从辅助气压压缩获益的患者亚组。
指南或共识出处
- PREVENT试验(Pneumatic Compression for Preventing VTE),ClinicalTrials.gov注册号NCT02040103,ISRCTN44653506。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The diagnostic performance of the available risk assessment models for VTE in patients who are critically ill receiving pharmacologic thromboprophylaxis is unclear.
RESEARCH QUESTION: For patients who are critically ill receiving pharmacologic thromboprophylaxis, do risk assessment models predict who would develop VTE or who could benefit from adjunctive pneumatic compression for thromboprophylaxis?
STUDY DESIGN AND METHODS: In this post hoc analysis of the Pneumatic Compression for Preventing VTE (PREVENT) trial, different risk assessment models for VTE (ICU-VTE, Kucher, Intermountain, Caprini, Padua, and International Medical Prevention Registry on VTE [IMPROVE] models) were evaluated. Receiver-operating characteristic curves were constructed, and the sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios were calculated. In addition, subgroup analyses were performed evaluating the effect of adjunctive pneumatic compression vs none on the study primary outcome.
RESULTS: Among 2,003 patients receiving pharmacologic thromboprophylaxis, 198 (9.9%) developed VTE. With multivariable logistic regression analysis, the independent predictors of VTE were Acute Physiology and Chronic Health Evaluation II score, prior immobilization, femoral central venous catheter, and invasive mechanical ventilation. All risk assessment models had areas under the curve < 0.60 except for the Caprini model (0.64; 95% CI, 0.60-0.68). The Caprini, Padua, and Intermountain models had high sensitivities (> 85%) but low specificities (< 20%) for predicting VTE, whereas the ICU-VTE, Kucher, and IMPROVE models had low sensitivities (< 15%) but high specificities (> 85%). The positive predictive values were low (< 20%) for all studied cutoff scores, whereas the negative predictive values were mostly > 90%. Using the risk assessment models to stratify patients into high- vs low-risk subgroups, the effect of adjunctive pneumatic compression vs pharmacologic prophylaxis alone did not differ across the subgroups (Pinteraction > .05).
INTERPRETATION: The risk assessment models for VTE performed poorly in patients who are critically ill receiving pharmacologic thromboprophylaxis. None of the models identified a subgroup of patients who might benefit from adjunctive pneumatic compression.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, No.: NCT02040103, URL: www.
CLINICALTRIALS: gov. ISRCTN44653506; International Standard Randomised Controlled Trial No.: ISRCTN44653506, URL: https://www.isrctn.com.
参考来源
- Al-Dorzi HM, Arishi H, Al-Hameed FM, et al. Performance of Risk Assessment Models for VTE in Patients Who Are Critically Ill Receiving Pharmacologic Thromboprophylaxis: A Post Hoc Analysis of the Pneumatic Compression for Preventing VTE Trial. Chest. 2024. PMID: 39232999. doi:10.1016/j.chest.2024.07.182
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。